Jpmorgan Chase & CO Galapagos Nv Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Galapagos Nv stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,187 shares of GLPG stock, worth $58,830. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,187

Previous 2,281 4.12%

Holding current value

$58,830

Previous $56,000 10.71%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$24.2 - $30.67 $2,274 - $2,882	-94 Reduced 4.12%	2,187 $62,000
Q2 2024 Aug 12, 2024	SELL	$24.78 - $32.48 $52,533 - $68,857	-2,120 Reduced 48.17%	2,281 $56,000
Q1 2024 May 10, 2024	BUY	$32.2 - $42.44 $141,519 - $186,523	4,395 Added 73250.0%	4,401 $141,000
Q4 2023 Feb 12, 2024	SELL	$31.87 - $40.71 $116,516 - $148,835	-3,656 Reduced 99.84%	6 $0
Q3 2023 Nov 14, 2023	BUY	$34.17 - $42.98 $107,635 - $135,387	3,150 Added 615.23%	3,662 $126,000
Q2 2023 Aug 11, 2023	BUY	$37.4 - $44.52 $486 - $578	13 Added 2.61%	512 $20,000
Q1 2023 May 11, 2023	BUY	$36.5 - $48.0 $1,277 - $1,680	35 Added 7.54%	499 $19,000
Q4 2022 Feb 13, 2023	SELL	$37.44 - $46.51 $18,607 - $23,115	-497 Reduced 51.72%	464 $21,000
Q3 2022 Nov 14, 2022	SELL	$42.27 - $57.6 $12.4 Million - $16.9 Million	-293,468 Reduced 99.67%	961 $41,000
Q2 2022 Aug 11, 2022	SELL	$52.3 - $71.59 $276,196 - $378,066	-5,281 Reduced 1.76%	294,429 $16.4 Million
Q1 2022 May 11, 2022	BUY	$51.32 - $68.5 $370,684 - $494,775	7,223 Added 2.47%	299,710 $18.6 Million
Q4 2021 Feb 10, 2022	BUY	$47.03 - $57.12 $10,346 - $12,566	220 Added 0.08%	292,487 $16.1 Million
Q3 2021 Nov 12, 2021	BUY	$52.17 - $70.2 $15.2 Million - $20.5 Million	292,267 New	292,267 $15.4 Million

Others Institutions Holding GLPG

# of Institutions

Shares Held

12.3M

Call Options Held

69.1K

Put Options Held

42.7K

View Full List

About GALAPAGOS NV

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.77B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

More about GLPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Galapagos Nv Transaction History